This is the first study to examine the potency of a second generation Hsp90 inhibitor, NVP-AUY922, on the inhibition of migration in CRC cells through the simultaneous inhibition of EMT effectors regulated by HMGA2. Here, HMGA2 is linked to colorectal carcinoma.